Clinical Trial

A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of VCT220 (other name: CX11) in subjects with moderate renal impairment compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function. The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations of VCT220 in subjects with renal impairment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-08.
Status change: Recruiting → Completed 2026-03-25
Trial Details
NCT Number NCT07347808
Lead Sponsor Vincentage Pharma Co., Ltd
Conditions Obesity & Overweight
Enrollment 16 participants
Start Date 2025-12-25
Primary Completion 2026-01-18 (estimated)
Study Completion 2026-02-18 (estimated)
Updated on ClinicalTrials.gov 2026-03-27